Related Experiment Video

Updated: May 26, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

P2Y12 inhibitors adjunctive to primary PCI therapy in STEMI: fighting against the activated platelets

Dimitrios Alexopoulos1

  • 1Department of Cardiology, Patras University Hospital, Rion 26500, Patras, Greece.

International Journal of Cardiology
|December 24, 2011
PubMed

Insights

For ST-elevation myocardial infarction (STEMI), potent P2Y12 inhibitors like prasugrel and ticagrelor offer superior antiplatelet effects compared to clopidogrel, improving reperfusion during primary percutaneous coronary intervention (PPCI).

Area of Science:

  • Cardiology
  • Pharmacology
  • Thrombosis

Background:

  • ST-elevation myocardial infarction (STEMI) is a critical condition requiring rapid reperfusion.
  • Platelet activation is significantly heightened in STEMI, creating a pro-thrombotic state.
  • Effective antiplatelet therapy is essential for optimal outcomes following primary percutaneous coronary intervention (PPCI).

Purpose of the Study:

  • To evaluate the role and efficacy of P2Y12 inhibitors as adjunctive therapy in PPCI for STEMI.
  • To compare the effectiveness of clopidogrel versus newer P2Y12 inhibitors (prasugrel, ticagrelor) in the STEMI setting.
  • To discuss the potential utility of genetic or phenotypic testing for guiding P2Y12 inhibitor selection.

Main Methods:

  • Review of current clinical practices and available literature on P2Y12 inhibitor use in STEMI.
  • Comparative analysis of the pharmacological profiles of clopidogrel, prasugrel, and ticagrelor regarding platelet inhibition.
  • Discussion of clinical trial data on the efficacy and safety of these agents in STEMI patients undergoing PPCI.

Main Results:

  • Clopidogrel demonstrates slower, weaker, and more variable platelet inhibition, potentially suboptimal for STEMI.
  • Newer P2Y12 inhibitors, prasugrel and ticagrelor, exhibit more potent and consistent antiplatelet activity.
  • These newer agents show a favorable action profile in the context of the hyper-activated platelets characteristic of STEMI.

Conclusions:

  • Potent P2Y12 inhibitors (prasugrel, ticagrelor) are likely superior to clopidogrel for STEMI patients undergoing PPCI.
  • Further research is needed to address safety, efficacy, and personalized selection strategies, including genetic/phenotypic approaches.
  • Unanswered clinical questions remain regarding optimal P2Y12 inhibitor use in STEMI management.

More Related Videos

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Ferric Chloride-induced Murine Thrombosis Models10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...